David Miller, BA

Sr. Director, Strategic Communications
Curevo Vaccine

Disclosure(s): Curevo Vaccine: Employee, Stocks/Bonds (Private Company)

Poster(s):

• (P-597) Amezosvatein Demonstrates Non-Inferior Immunogenicity and Superior Tolerability Head-to-Head vs Shingrix in a Phase 2 Herpes Zoster Vaccine Trial
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT